Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MF, MF · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | - |
| Group 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MF | DEVICE | One evening dose of dry powder inhaled MF 400 μg (Multidose device). |
Inclusion Criteria: * Must be \>=18 years of age, of either gender \& of any race. * Must have had a diagnosis of asthma for at least 6 months, characterized by recurrent episode of wheezing, breathlessness, chest tightness \& coughing. * Baseline FEV1 must be \>=55% and \<=85% of predicted at the ...
MF is an investigational drug being studied for the treatment of asthma. It is currently in Phase 3 clinical development. The drug is being evaluated for its efficacy and safety in patients with asthma, as part of a controlled clinical trial.
MF is being developed by Organon & Co., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol OGN. The company is conducting clinical trials to evaluate the drug's potential in treating asthma.
MF is currently in Phase 3 clinical development. It has completed one Phase 3 trial, which was a controlled study involving 93 participants with asthma. The drug remains investigational and has not been approved by regulatory authorities.
MF has been studied in a Phase 3 clinical trial with the identifier NCT00817817. This completed trial, titled 'A Study to Determine the Efficacy and Safety of Two Mometasone Dry Powder Inhalers in the Treatment of Asthma (Study P02524)', enrolled 93 adults aged 18 years and older with asthma.
MF is a drug being developed by Organon & Co. for asthma. The clinical trial for MF involves mometasone dry powder inhalers, suggesting that MF may be related to mometasone, a corticosteroid used in asthma treatment. However, the specific relationship between MF and mometasone is not fully detailed.